A Phase I clinical trial investigating the combination of osimertinib and ABT-263 (Navitoclax) for the treatment of LC patients with EGFR mutations, following the failure of EGFR-TKI therapy, utilized a dosage regimen of 80 mg/day of osimertinib and 150 mg/day of Navitoclax. The gene discussed is EGFR; the disease is laryngotracheoesophageal cleft.